EN | RU
EN | RU

Help Support

Back

High-titer convalescent plasma reduces COVID-19 progression

High-titer convalescent plasma reduces COVID-19 progression High-titer convalescent plasma reduces COVID-19 progression
High-titer convalescent plasma reduces COVID-19 progression High-titer convalescent plasma reduces COVID-19 progression

A double-blind, randomized, placebo-controlled trial was performed to determine whether convalescent plasma with elevated titers of antibodies against SARS-CoV-2, administered within 72 hours after the onset of mild infection symptoms, would effectively prevent the advancement to severe disease in coronavirus disease 2019 (COVID-19)-infected geriatrics. 

See All

Key take away

Early administration of elevated-titer convalescent plasma against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was found to minimize the progression risk to severe respiratory disease by 48% in  older patients suffering from coronavirus.

Background

A double-blind, randomized, placebo-controlled trial was performed to determine whether convalescent plasma with elevated titers of antibodies against SARS-CoV-2, administered within 72 hours after the onset of mild infection symptoms, would effectively prevent the advancement to severe disease in coronavirus disease 2019 (COVID-19)-infected geriatrics. 

Method

This trial enrolled 160 older patients infected with the coronavirus. Participants were allocated to receive either a placebo (0.9% normal saline) or convalescent plasma with high antibody titers against SARS-CoV-2.

The major outcome was severe respiratory disorder (respiratory rate of 30 breaths/minute or more, an oxygen saturation of < 93% while the subject was breathing ambient air, or both). This analysis was terminated early at 76% of its projected sample size. This was due to a substantial decline in coronavirus cases in the study region and thus steady recruitment of participants was not possible. 

Result

In the intention-to-treat population, the severe respiratory disease was found to develop in 16% (13/80) patients who were given convalescent plasma and 31% (25/80) patients (31%) who were given a placebo, with a relative risk decline of 48%.

In the time-to-event analysis, the median time to the development of severe respiratory disease in the convalescent plasma cohort was longer compared to the placebo cohort, as shown in the following figure:


A modified intention-to-treat assessment that excluded six subjects who had a primary end-point event prior to infusion illustrated a greater effect size. No vital adverse effects were witnessed. 

Conclusion

Early high-titer plasma therapy aids in the prevention of severe COVID-19 in older patients.

Source:

The New England Journal of Medicine

Article:

Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults

Authors:

Romina Libster et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: